Use of medications for secondary prevention in stroke patients at hospital discharge in Australia

International Journal of Clinical Pharmacy

Volumn 36, Issue 2, 2014, Pages 384-393

  Eissa, Ashraf ^a   Krass, Ines ^a   Bajorek, Beata V ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Australia; Cerebrovascular accident; Clinical audit; Medical care; Secondary prevention; Stroke

Indexed keywords

AMLODIPINE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DILTIAZEM; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IRBESARTAN; LERCANIDIPINE; LISINOPRIL; METOPROLOL; NIFEDIPINE; OLMESARTAN; PERINDOPRIL; PINDOLOL; PROPRANOLOL; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VERAPAMIL; FIBRINOLYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUSTRALIA; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; EVIDENCE BASED PRACTICE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD REVIEW; MONOTHERAPY; PRIORITY JOURNAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION; STROKE PATIENT; TERTIARY CARE CENTER; ADOLESCENT; ADULT; ATRIAL FIBRILLATION; CHILD; INFANT; MIDDLE AGED; PRESCHOOL CHILD; STROKE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; AUSTRALIA; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFANT; MALE; MIDDLE AGED; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; STROKE;

EID: 84899917889     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-013-9908-3     Document Type: Article

References (37)

1. Donnan G, Fisher M, Macleod M, Davis S. Stroke. The Lancet. 2008;371:1612-23. (Pubitemid 351626845)
2. Islam MS, Anderson CS, Hankey GJ. Trends in incidence and outcome of stroke in Perth, Western Australia during 1989-2001. Stroke. 2008;139:776-82. (Pubitemid 351619550)
3. Rothwell PM, Coull AJ, Giles MF. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004. Lancet. 2004;363:1925-33. (Pubitemid 38759651)
4. National stroke foundation (Internet). National Stroke Audit - Acute Services Clinical Audit Report 2011, Melbourne, Australia; 2011. [cited 2013 October 9) ISBN 978-0-9805933-7-2 Available from: http://strokefoundation.com. au/site/media/National-stroke-audit-acute-services-clinical-audit-report-2011. pdf.
5. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth community stroke study. Stroke. 2004;35:731-5. (Pubitemid 38280850)
6. National stroke foundation (Internet). Clinical Guidelines for Stroke Management 2010. Melbourne Australia; 2010. [cited 2013 October 9) ISSBN0-978-0-9805933-3-4 Available from:http://strokefoundation.com.au/site/ media/Clinical-Guidelines-Acute-Management-Recommendations-2010.pdf.
7. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001;119:300S-20S. (Pubitemid 32154207)
8. Kokotailo R, Hill M. Coding of stroke and stroke risk factors using international classification of diseases. Stroke. 2005;36:1776-81. (Pubitemid 41098778)
9. Corella D, Qi L, Tai ES, Deurenberg-Yap M, Tan CE, Chew SK, et al. Perilipin gene variation determines higher susceptibility to insulin resistance in Asian women when consuming a high-saturated fat, low-carbohydrate diet. Diabetes Care. 2006;29:1313-9. (Pubitemid 44125928)
10. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Inter-observer agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-7.
11. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American heart association/American stroke association stroke council. Stroke. 2007;38:1655-711.
12. Ovbiagele B, Hills NK, Saver JL, Johnston SC. Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA. Neurology. 2006;66:313-8. (Pubitemid 43739929)
13. Bajorek B, Krass I, Ogle S, Duguid M, Shenfield G. The impact of age on antithrombotic use in elderly patients with non-valvular atrial fibrillation. Australas J Ageing. 2002;21:36-41.
14. Munoz M, Marrugat J. Secondary prevention of coronary heart disease is less aggressive in patients over 64 years. Rev Esp Cardiol. 2003;56:586-93. (Pubitemid 36896689)
15. Philippe F, Danchin N, Quentzel S. Utilization of the principal therapeutic classes for cardiovascular prevention in elderly patients seen by cardiologists. Ann Cardiol Angeiol. 2004;53:339-46. (Pubitemid 39530757)
16. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol. 2003;55:604-8. (Pubitemid 36783203)
17. Strandberg T, Pitkala K, Kulp S. Use of cardiovascular drugs by home-dwelling coronary patients aged 75 years and older. A population based cross-sectional survey in helsinki, finland. Eur J Clin Pharmacol. 2001;57:513-6.
18. Lawlor D, Whincup P, Emberson JR. The challenge of secondary prevention for coronary heart disease in older patients: findings from the British women's heart and health study and the British regional heart study. Fam Pract. 2004;21:582-6. (Pubitemid 39317718)
19. Castelino RL, Chen TF, Guddattu V, Bajorek BV. Use of evidence-based therapy for the prevention of cardiovascular events among older people. Eval Health Prof. 2010;33:276-301.
20. Bajorek BV, Ren S. Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now. Int J Clin Pharm. 2012;34:88-97.
21. Sanossian N, Ovbiagele B. Prevention and management of stroke in very elderly patients. Lancet Neurol. 2009;8:1031-41.
22. EAFT (European Atrial Fibrillation Trial). Study group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-62.
23. Rigler SK, Webb MJ, Patel AT, Lai SM, Duncan PW. Use of antihypertensive and antithrombotic medications after stroke in community-based care. Ann Pharmacother. 2001;35:811-6. (Pubitemid 32678699)
24. Lichtman JH, Naert L, Allen NB, Watanabe E, Jones SB, Barry LC, et al. Use of antithrombotic medications among elderly ischemic stroke patients. Circ Cardiovasc Qual Outcomes. 2011;4:30-8.
25. Glader EL, Stegmayr B, Norrving B, Terént A, Hulter-Asberg K, Wester PO, et al. Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: a Swedish national perspective. J Intern Med. 2004;255:22-32. (Pubitemid 38121918)
26. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American heart association/American stroke association council on stroke. Stroke. 2006;37:577-617.
27. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381-91.
28. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
29. Diener HC, Bogousslavsky J, Brass LM. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331.
30. Bhatt DL, Fox KA, Hacke W. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706.
31. Usman MH, Notaro LA, Nagarakanti R. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol. 2009;103:1107.
32. National stroke foundation (Internet). National Stroke Audit Acute Services Organisational Survey Report 2009. Melbourne Australia; 2009. (cited 2013 October 9) ISBN0-9752292-4-6 Available from: http://strokefoundation.com. au/site/media/National-stroke-audit-acute-services-organisational-survey-report- 2009.pdf.
33. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.
34. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342:145-53.
35. Reid C, Nelson MR, Shiel L, Chew D, Connor G, DeLooze F. Australians at risk: management of cardiovascular risk factors in the REACH Registry. Heart Lung Circ. 2008;17:114-8. (Pubitemid 351377555)
36. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-63.
37. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med. 2003;163:669-76. (Pubitemid 36343359)